A Phase 4 interventional study of Culprit lesion only PCI and Immediate multi-vessel PCI in Cardiogenic Shock, Acute Myocardial Infarction and Multi Vessel Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.
Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.
Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 6th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Min-Seok Kim · Sites in Korea, Republic of
Ages 19+
Min-Seok Kim · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 560 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 280 across the 10 interventional studies, 1,000 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 6 most frequent:
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 6 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Cardiogenic with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05698628Min-Seok KimDistal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO | 2027-02-28 |
| NCT06078436Min-Seok KimPulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).
Cardiogenic shock (CS) is a fatal complication of acute myocardial infarction (AMI). Until now, in this setting, it has been well-known that early revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) was associated with improved clinical outcomes although the rate of mortality remains still high in the mechanical circulatory support (MCS) era. In real-world practice, since clinically significant non-infarct related artery (non-IRA) stenosis or occlusion in addition to an IRA can be found in 70% to 80% of patients with AMI complicated by CS, the decision of revascularization strategy is a crucial issue to improve clinical outcomes in CS patients with multivessel disease. The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) and the 2017 European Society of Cardiology (ESC) guidelines recommend considering PCI of severe stenosis in non-IRA during a primary procedure to improve overall myocardial perfusion and hemodynamic stability for patients with AMI and CS. However, the CULPRIT-SHOCK trial, which is the largest randomized trial in CS, demonstrated the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was higher in the immediate multi-vessel PCI than in the culprit lesion-only PCI group. In this regard, the recently updated guidelines do not recommend the routine non-IRA revascularization during primary PCI and it should be considered in selected cases in which there is a very severe flow-limiting non-IRA stenosis irrigating a large myocardial area. Nevertheless, there is still some unsolved issue regarding the role of non-IRA revascularization in AMI patients with CS. Majority of enrolled patients in the CULPRIT-SHOCK trial might have a mild form of CS (median systolic blood pressure of 100) and few patients received MCS devices (28.3% of study population). Furthermore, the mortality benefits of culprit-only PCI were attenuated at 1-year follow-up with an increased risk of repeat revascularization and hospitalization for heart failure. In contrast to the CULPRIT-SHOCK trial, the recent large United State registry from National Cardiovascular Data Registry demonstrated that the benefits of multi-vessel PCI in patients with non-ST-segment elevation MI and CS was more pronounced in those requiring MCS. In addition, recent data from the Korea Acute Myocardial Infarction National Health Registry showed that multivessel PCI was associated with a lower risk of all-cause death than culprit-only PCI, suggesting possible benefit of nonculprit lesion revascularization during the index hospitalization on long-term clinical outcomes.
Therefore, the current randomized trial sought to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with advanced form of CS patients who requiring veno-arterial extracorporeal membrane oxygenator (VA-ECMO).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive culprit-lesion only PCI.
Procedure: Culprit lesion only PCI
Patients will receive immediate multi-vessel PCI.
Procedure: Immediate multi-vessel PCI
Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio. This group will be taken culprit-lesion only PCI during primary PCI.
Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio. This group will be taken immediate multi-vesesl PCI during primary PCI.
Rates of all-cause mortality or advanced heart failure requiring cardiac replacement therapy
all-cause mortality or requiring left ventricular assisted device (LVAD) insertion or heart transplantation)
Time frame: 90 days after primary PCI
Rates of In-hospital mortality
Death by any cause in hospital
Time frame: Up to 30 days
Rates of In-hospital cardiac mortality
Death by cardiac cause in hospital
Time frame: Up to 30 days
Rates of VA-ECMO weaning success
Successful weaning of VA-ECMO was defined as successful removal of VA-ECMO and not requiring further mechanical support because of recurring cardiogenic shock over the following 48 hours.
Time frame: Up to 30 days
Time to VA-ECMO weaning
Time from VA-ECMO insertion to VA-ECMO weaning
Time frame: Up to 30 days
Rates of critical limb ischemia after successful VA-ECMO weaning
Critical limb ischemia is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity. (Rutherford classification 4, 5, or 6)
Time frame: Up to 30 days
Cerebral Performance Category (CPC) 3-5 at discharge
Neurologic performance scale at discharge
Time frame: Up to 30 days
Length of intensive-care unit (ICU) stay
ICU stay day
Time frame: Up to 30 days
Total procedural time
Procedural time (minutes)
Time frame: Immediate after the index procedure
Total amount of contrast use
Contrast use (cc)
Time frame: Immediate after the index procedure
Rates of all-cause mortality
Death by any cause
Time frame: 90 Days and 12 months after primary PCI
Rates of cardiac mortality
Death by cardiac cause
Time frame: 90 Days and 12 months after primary PCI
Requirement of cardiac replacement therapy
LVAD insertion or heart transplantation
Time frame: 90 Days and 12 months after primary PCI
Requirement of renal replacement therapy
Continuous renal replacement therapy, hemodialysis, or peritoneal dialysis
Time frame: 90 Days and 12 months after primary PCI
Rates of myocardial infarction (MI)
spontaneous MI during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of MI related to culprit vessel
MI related to culprit vessel during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of MI related to non-culprit vessel
MI related to non-culprit vessel during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of stent thrombosis
Academic Research Consortium (ARC)-defined definite or probable stent thrombosis
Time frame: 90 Days and 12 months after primary PCI
Rates of Re-hospitalization due to heart failure
Re-hospitalization due to heart failure during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of Re-hospitalization due to any cause
Re-hospitalization due to any cause during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of target-lesion revascularization (TLR)
TLR during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of target-vessel revascularization (TVR)
TVR during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of repeat revascularization
Repeat revascularization during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of cerebrovascular accident
Cerebrovascular accident during follow-up
Time frame: 90 Days and 12 months after primary PCI
Rates of bleeding
Bleeding ARC \[BARC\] type 2, 3, or 5
Time frame: 90 Days and 12 months after primary PCI
Rates of major bleeding
(BARC type 3 or 5
Time frame: 90 Days and 12 months after primary PCI
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.